[go: up one dir, main page]

DK1325130T3 - Nogo-Receptorhomologer - Google Patents

Nogo-Receptorhomologer

Info

Publication number
DK1325130T3
DK1325130T3 DK01979595.4T DK01979595T DK1325130T3 DK 1325130 T3 DK1325130 T3 DK 1325130T3 DK 01979595 T DK01979595 T DK 01979595T DK 1325130 T3 DK1325130 T3 DK 1325130T3
Authority
DK
Denmark
Prior art keywords
proteins
nogo
methods
compositions
specifically
Prior art date
Application number
DK01979595.4T
Other languages
English (en)
Inventor
Stephen M Strittmatter
Richard L Cate
Dinah W Y Sah
Original Assignee
Univ Yale
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Yale, Biogen Idec Inc filed Critical Univ Yale
Application granted granted Critical
Publication of DK1325130T3 publication Critical patent/DK1325130T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
DK01979595.4T 2000-10-06 2001-10-06 Nogo-Receptorhomologer DK1325130T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23836100P 2000-10-06 2000-10-06
PCT/US2001/031488 WO2002029059A2 (en) 2000-10-06 2001-10-06 Nogo receptor homologs

Publications (1)

Publication Number Publication Date
DK1325130T3 true DK1325130T3 (da) 2010-05-25

Family

ID=22897532

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01979595.4T DK1325130T3 (da) 2000-10-06 2001-10-06 Nogo-Receptorhomologer

Country Status (12)

Country Link
US (5) US20030124704A1 (da)
EP (1) EP1325130B1 (da)
JP (2) JP4465148B2 (da)
AT (1) ATE458815T1 (da)
AU (2) AU1153902A (da)
CA (1) CA2424834A1 (da)
DE (1) DE60141409D1 (da)
DK (1) DK1325130T3 (da)
ES (1) ES2341608T3 (da)
NZ (1) NZ525422A (da)
PT (1) PT1325130E (da)
WO (1) WO2002029059A2 (da)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7119165B2 (en) 2000-01-12 2006-10-10 Yale University Nogo receptor-mediated blockade of axonal growth
WO2002029059A2 (en) * 2000-10-06 2002-04-11 Yale University Nogo receptor homologs
AU2002331180A1 (en) * 2001-08-27 2003-03-10 Novartis Pharma Gmbh Nogo receptor homologues and their use
US20050221420A1 (en) * 2001-10-22 2005-10-06 Carmen Barske Nogo receptor homologues and their use
US7309485B2 (en) * 2001-12-03 2007-12-18 Children's Medical Center Corporation Reducing myelin-mediated inhibition of axon regeneration
WO2004005510A1 (ja) * 2002-07-05 2004-01-15 Shionogi & Co., Ltd. 新規Nogo受容体様ポリペプチドおよびそのＤＮＡ
KR20050062525A (ko) * 2002-08-10 2005-06-23 예일 유니버시티 Ｎｏｇｏ 수용체 길항제
SI1606409T1 (sl) 2003-03-19 2011-01-31 Biogen Idec Inc Vezavni protein receptorja Nogo
AU2004227392A1 (en) 2003-04-04 2004-10-21 University Of Rochester Identification of novel nogo-receptors and methods related thereto
US20070065429A1 (en) * 2003-04-16 2007-03-22 Biogen Idec Ma Inc. Nogo-receptor antagonists for the treatment of conditions involving amyloid plaques
US20080274112A1 (en) * 2003-08-07 2008-11-06 Lee Daniel H S Nogo Receptor Antagonists
US8912144B2 (en) * 2003-12-16 2014-12-16 Children's Medical Center Corporation Method for treating stroke via administration of NEP1-40 and inosine
EP1695061A4 (en) * 2003-12-16 2008-02-20 Childrens Medical Center METHOD OF TREATING NEUROLOGICAL DISORDERS
EP1713494A2 (en) * 2004-01-30 2006-10-25 Biogen Idec MA, Inc. Treatment of conditions involving dopaminergic neuronal degeneration using nogo receptor antagonists
PT1776136E (pt) 2004-06-24 2012-12-05 Biogen Idec Inc Tratamento de estados que envolvem desmielinização
CA2582581A1 (en) * 2004-10-01 2006-05-04 Yale University Nogo-a polypeptide fragments, variant nogo receptor-1 polypeptides, and uses thereof
WO2007008732A2 (en) * 2005-07-07 2007-01-18 Yale University Compositions and methods for suppressing axonal growth inhibition
CN101495509B (zh) 2005-07-08 2015-04-22 比奥根艾迪克Ma公司 Sp35抗体及其用途
JP2009505665A (ja) * 2005-08-25 2009-02-12 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｎｏｇｏ受容体ポリペプチドおよびポリペプチドフラグメント、ならびにそれらの使用
WO2007089601A2 (en) 2006-01-27 2007-08-09 Biogen Idec Ma Inc. Nogo receptor antagonists
WO2007133746A2 (en) * 2006-05-15 2007-11-22 Biogen Idec Ma Inc. Use of nogo receptor-1 (ngr1) antagonists for promoting oligodendrocyte survival
WO2007137303A2 (en) * 2006-05-24 2007-11-29 Myelin Repair Foundation, Inc. Permeability of blood-brain barrier
US20100047232A1 (en) * 2006-11-14 2010-02-25 Jasvinder Atwal Modulators of neuronal regeneration
RU2447449C2 (ru) * 2006-11-14 2012-04-10 Дженентек, Инк. Модуляторы нейрональной регенерации
WO2009009743A2 (en) * 2007-07-12 2009-01-15 Institute For Advance Study Sequence optimization for expression of a foreign gene
CN101971034A (zh) * 2007-12-11 2011-02-09 健泰科生物技术公司 神经元再生的调控剂
EP2276500A4 (en) 2008-03-13 2015-03-04 Univ Yale REACTIVATION OF AXON GROWTH AND AXON RECOVERY IN CHRONIC REVERSE MARKET INJURIES
US20090285803A1 (en) * 2008-05-13 2009-11-19 Jasvinder Atwal ANTI-PirB ANTIBODIES
US8058406B2 (en) 2008-07-09 2011-11-15 Biogen Idec Ma Inc. Composition comprising antibodies to LINGO or fragments thereof
EP2392208B1 (en) * 2010-06-07 2016-05-04 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Fusion proteins comprising a DNA-binding domain of a Tal effector protein and a non-specific cleavage domain of a restriction nuclease and their use
US9120111B2 (en) 2012-02-24 2015-09-01 Rain Bird Corporation Arc adjustable rotary sprinkler having full-circle operation and automatic matched precipitation
NZ702178A (en) 2012-05-14 2017-01-27 Biogen Ma Inc Lingo-2 antagonists for treatment of conditions involving motor neurons
US9156043B2 (en) 2012-07-13 2015-10-13 Rain Bird Corporation Arc adjustable rotary sprinkler with automatic matched precipitation
EP3242893A1 (en) 2015-01-08 2017-11-15 Biogen MA Inc. Lingo-1 antagonists and uses for treatment of demyelinating disorders

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5250414A (en) 1988-11-04 1993-10-05 Erziehungsdirektion Of The Canton Zurich Diagnostic methods using neurite growth regulatory factors
WO1990005191A1 (en) 1988-11-04 1990-05-17 Erziehungsdirektion Of The Canton Zurich Neurite growth regulatory factors
CA1341050C (en) 1988-11-04 2000-07-11 Martin E. Schwab Neurite growth regulatory factors
AU5891394A (en) 1993-02-11 1994-08-29 Erziehungsdirektion Of The Canton Zurich A combination of neurotrophin and antibody directed toward myelin-associated neurite growth inhibitory protein promotes central nervous system regeneration
WO2000073452A2 (en) 1999-06-02 2000-12-07 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US5858708A (en) * 1996-08-12 1999-01-12 Bandman; Olga Polynucleotides encoding two novel human neuroendocrine-specific proteins
EP1002132A4 (en) * 1997-08-05 2005-04-27 Human Genome Sciences Inc HUMAN SECRETED PROTEINS
NZ507435A (en) 1998-03-10 2003-12-19 Genentech Inc Novel polypeptides and nucleic acids with homology to cornichon
AU4682999A (en) 1998-06-16 2000-01-05 Human Genome Sciences, Inc. 94 human secreted proteins
PT1098972E (pt) 1998-07-22 2010-12-14 Smithkline Beecham Ltd Proteína semelhante a proteína especificamente neuroendócrina e adnc codificante
NZ511683A (en) * 1998-11-06 2004-06-25 Martin E Schwab Nucleotide and protein sequences of nogo genes and methods based thereon for treatment of diseases that result in damage to the central system
MXPA01005169A (es) 1998-12-01 2002-07-02 Genentech Inc Promocion o inhibicion deangiogenesis y cardiovascularizacion.
MXPA01006330A (es) 1998-12-22 2002-07-02 Genentech Inc Metodos y composiciones para inhibir el crecimiento de celulas neoplasticas.
CA2362427A1 (en) 1999-03-08 2000-09-14 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
AU2883600A (en) 1999-03-08 2000-09-28 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
CA2383592A1 (en) 1999-03-31 2000-10-05 Curagen Corporation 2384891 acids including open reading frames encoding polypeptides; orfx
AU3632600A (en) 1999-05-14 2000-12-05 Genentech Inc. Compositions and methods for the treatment of immune related diseases
EP1268506A4 (en) 1999-07-30 2004-07-28 Millennium Pharm Inc SECRET PROTEINS AND THEIR USE
AU2575901A (en) * 1999-12-08 2001-06-18 Millennium Pharmaceuticals, Inc. Novel leucine rich repeat-containing molecules and uses therefor
US7119165B2 (en) * 2000-01-12 2006-10-10 Yale University Nogo receptor-mediated blockade of axonal growth
GEP20063830B (en) * 2000-01-12 2006-05-25 Univ Yale Nogo Receptor-Mediated Blockade of Axonal Growth
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
US6695956B2 (en) 2000-04-18 2004-02-24 Teijin Limited Oxygen concentrating apparatus
WO2002029059A2 (en) * 2000-10-06 2002-04-11 Yale University Nogo receptor homologs
AU2002331180A1 (en) 2001-08-27 2003-03-10 Novartis Pharma Gmbh Nogo receptor homologues and their use
US20050221420A1 (en) * 2001-10-22 2005-10-06 Carmen Barske Nogo receptor homologues and their use
KR20050062525A (ko) * 2002-08-10 2005-06-23 예일 유니버시티 Ｎｏｇｏ 수용체 길항제

Also Published As

Publication number Publication date
CA2424834A1 (en) 2002-04-11
JP2004528809A (ja) 2004-09-24
US20030124704A1 (en) 2003-07-03
WO2002029059A3 (en) 2003-01-23
JP2009100767A (ja) 2009-05-14
JP4465148B2 (ja) 2010-05-19
US7173118B2 (en) 2007-02-06
EP1325130A2 (en) 2003-07-09
US20050048520A1 (en) 2005-03-03
ES2341608T3 (es) 2010-06-23
PT1325130E (pt) 2010-05-31
WO2002029059A9 (en) 2003-05-15
EP1325130B1 (en) 2010-02-24
ATE458815T1 (de) 2010-03-15
AU1153902A (en) 2002-04-15
US20110129477A1 (en) 2011-06-02
US7456255B2 (en) 2008-11-25
DE60141409D1 (de) 2010-04-08
US20090175850A1 (en) 2009-07-09
NZ525422A (en) 2006-09-29
AU2002211539B2 (en) 2007-01-25
WO2002029059A2 (en) 2002-04-11
US20070104713A1 (en) 2007-05-10

Similar Documents

Publication Publication Date Title
DK1325130T3 (da) Nogo-Receptorhomologer
MXPA02006885A (es) Bloqueo del crecimiento axonal mediado por receptor de nogo.
WO2003031462A3 (en) Nogo receptor-mediated blockade of axonal growth
DE60028970D1 (de) An her2 bindende peptidverbindungen
CY1111912T1 (el) Μεθοδος αναστολης της δραστηριοτητας των οστεοκλαστων
DK1434791T3 (da) Specifikke bindingsmidler til human angiopoietin-2
ME00184B (me) Osteoprotegerin vezujući proteini i receptori
WO2002044320A3 (en) Human elongase genes and uses thereof
WO2004019893A3 (en) Modulators of angiogenesis
ATE543833T1 (de) Bmp-7-varianten-zusammensetzungen, verfahren und verwendungen
EP1436308A4 (en) ANTISENSE MODULATION OF IL-1 RECEPTOR ASSOCIATED KINASE-4 EXPRESSION
HUP0402327A2 (hu) Inzulinszerű növekedési faktort kötő 5-ös fehérje expressziójának antiszensz módosítása
DE59809283D1 (de) Inhibitoren für den urokinaserezeptor
WO2010065536A3 (en) Recombinant bone marrow stromal antigen-2 in the treatment of autoimmune diseases
WO2003082206A3 (en) Multiple sclerosis-related immunoglobulin derived proteins, compositions, methods and uses
ATE407944T1 (de) Mit trp-proteinen verwandtes protein mtr1 und dieses codierende dna-sequenz
DE69529235D1 (de) Menschliche dnase i varianten
WO2002000834A3 (fr) Nouveau polypeptide, proteine phosphatase humaine 9.68, et polynucleotide codant ce polypeptide
WO2002062996A1 (fr) Nouveau peptide physiologiquement actif et utilisation de ce peptide
DE50000562D1 (de) Mittel zur behandlung von pigmentierungsstörungen
TW200635950A (en) Specific binding agents of human angiopoietin-2